blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP0775155

EP0775155 - ESTRA-1,3,5(10)-TRIENE DERIVATIVES, METHODS OF PREPARING SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.03.2005
Database last updated on 09.09.2024
Most recent event   Tooltip19.09.2008Change - representativepublished on 22.10.2008  [2008/43]
Applicant(s)For all designated states
Schering AG
Müllerstrasse 178
13353 Berlin / DE
[2003/40]
Former [1997/35]For all designated states
Jenapharm GmbH & Co. KG
Otto-Schott-Strasse 15
07745 Jena / DE
Former [1997/22]For all designated states
JENAPHARM GmbH
Otto-Schott-Strasse 15
D-07745 Jena / DE
Inventor(s)01 / SIEMANN, Hans-Joachim
-
verstorben / DE
02 / SCHWARZ, Sigfrid
Ottogerd-Mühlmann-Strasse 17
D-07743 Jena / DE
03 / ELGER, Walter
Schorlemerallee 12b
D-14195 Berlin / DE
04 / REDDERSEN, Gudrun
Hügelstrasse 25
D-07749 Jena / DE
05 / SCHNEIDER, Birgitt
Damaschkeweg 19
D-07745 Jena / DE
[1997/22]
Representative(s)Ziebig, Marlene, et al
Gulde Hengelhaupt
Ziebig & Schneider
Wallstraße 58/59
DE-10179 Berlin / DE
[N/P]
Former [2008/43]Ziebig, Marlene, et al
Gulde Hengelhaupt Ziebig & Schneider Patentanwälte Rechtsanwälte Wallstrasse 58/59
10179 Berlin / DE
Former [2003/31]Ziebig, Marlene K., Dr., et al
Anwaltskanzlei, Gulde Hengelhaupt Ziebig & Schneider, Schützenstrasse 15-17
10117 Berlin / DE
Former [2003/25]Rasch, Dorit, et al
c/o Anwaltskanzlei, Gulde Hengelhaupt Ziebig & Schneider, Schützenstrasse 15-17
10117 Berlin / DE
Former [1997/22]Wablat, Wolfgang, Dr.Dr.
Patentanwalt, Dr. Dr. W. Wablat, Potsdamer Chaussee 48
14129 Berlin / DE
Application number, filing date95925679.303.07.1995
[1997/22]
WO1995DE00877
Priority number, dateDE1994442939709.08.1994         Original published format: DE 4429397
[1997/22]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO9605216
Date:22.02.1996
Language:DE
[1996/09]
Type: A1 Application with search report 
No.:EP0775155
Date:28.05.1997
Language:DE
The application published by WIPO in one of the EPO official languages on 22.02.1996 takes the place of the publication of the European patent application.
[1997/22]
Type: B1 Patent specification 
No.:EP0775155
Date:06.05.2004
Language:DE
[2004/19]
Search report(s)International search report - published on:EP22.02.1996
ClassificationIPC:C07J41/00, A61K31/56, C07J53/00, C07J43/00
[1997/22]
CPC:
C07J43/003 (EP,US); A61P15/00 (EP); A61P15/18 (EP);
A61P5/24 (EP); A61P5/26 (EP); A61P5/30 (EP);
A61P5/34 (EP); C07J41/0072 (EP,US); C07J51/00 (EP,US);
C07J53/004 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [1997/22]
TitleGerman:ESTRA-1,3,5(10)-TRIEN-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN[1997/22]
English:ESTRA-1,3,5(10)-TRIENE DERIVATIVES, METHODS OF PREPARING SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM[1997/22]
French:DERIVES ESTRA-1,3,5(10)-TRIENE, LEURS PROCEDES DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT[1997/22]
Entry into regional phase20.01.1997National basic fee paid 
20.01.1997Designation fee(s) paid 
20.01.1997Examination fee paid 
Examination procedure19.12.1995Request for preliminary examination filed
International Preliminary Examining Authority: EP
20.01.1997Examination requested  [1997/22]
03.06.1997Despatch of a communication from the examining division (Time limit: M08)
02.02.1998Reply to a communication from the examining division
27.05.1999Despatch of a communication from the examining division (Time limit: M02)
27.07.1999Reply to a communication from the examining division
12.04.2000Despatch of a communication from the examining division (Time limit: M06)
22.08.2000Reply to a communication from the examining division
05.10.2001Despatch of a communication from the examining division (Time limit: M04)
11.02.2002Reply to a communication from the examining division
15.05.2003Communication of intention to grant the patent
17.11.2003Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
16.01.2004Fee for grant paid
16.01.2004Fee for publishing/printing paid
Divisional application(s)EP02090252.4  / EP1284273
EP02090253.2  / EP1273590
Opposition(s)08.02.2005No opposition filed within time limit [2005/17]
Request for further processing for:16.01.2004Request for further processing filed
16.01.2004Full payment received (date of receipt of payment)
Request granted
09.03.2004Decision despatched
Fees paidRenewal fee
02.06.1997Renewal fee patent year 03
16.04.1998Renewal fee patent year 04
22.04.1999Renewal fee patent year 05
26.06.2000Renewal fee patent year 06
19.06.2001Renewal fee patent year 07
17.06.2002Renewal fee patent year 08
13.06.2003Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipGR06.08.2004
[2005/06]
Cited inInternational search[XY]DE1949095  (JENAPHARM VEB) [X] 1,3,4 * page 3, line 9 - line 18; examples 27-29 * [Y] 1-4;
 [XY]FR2133484  (JENAPHARM VEB [DD]) [X] 1,3,4 * page 2, line 14 - line 18; examples 21-23,25,27 * [Y] 1-4;
 [X]GB1317373  (JENAPHARM VEB) [X] 1,3,4 * examples 11-14,16 *;
 [X]GB1398026  (JENAPHARM VEB) [X] 1,3,4 * examples 2,4-6,18; claim 31 *;
 [XY]DD114806  (S. SCHWARTZ) [X] 1,3,4 * page 2, column 1, line 52 - line 59; examples 2-4,6,9,10 * [Y] 1-4;
 [Y]FR2429797  (JENAPHARM VEB [DD]) [Y] 1-4 * page 1, line 21 - line 33; examples 2,4,7 *;
 [XY]DD201143  (SCHWARZ SIGFRID, et al) [X] 1,3,4 * page 1, lines 6-8; examples 3-5 * [Y] 1-4;
 [XY]DD207447  (JENAPHARM VEB [DD]) [X] 1,3,4 * examples 1-5 * [Y] 1-4;
 [Y]EP0430386  (SCHERING AG [DE]) [Y] 1-4 * the whole document *;
 [Y]WO9401450  (SCHERING AG [DE], et al) [Y] 1-4* the whole document *
 [XY]  - SCHWARZ S ET AL, "Steroids. XI. 17.alpha.-Ethynylestradiol sulfamates", Z. CHEM., vol. 10, no. 8, pages 299 - 300 [X] 1,3,4 * the whole document * [Y] 1-4
 [XY]  - SCHWARZ S ET AL, "Steroids. 15. Sulfonyloxy derivatives of estrogens", PHARMAZIE, BERLIN DE, vol. 30, no. 1, pages 17 - 21 [X] 1,3,4 * siehe verbindungen 18-25, 28-32, 59-62, 80, 81 und 110-113 * [Y] 1-4
 [XY]  - STOELZNER W ET AL, "Dissociation of the antigonadotrophic and the contraceptive activities of certain estratriene derivatives", PHARMAZIE, BERLIN DE, vol. 30, no. 1, pages 52 - 53 [X] 1,3,4 * the whole document * [Y] 1-4
 [XY]  - SHU H D ET AL, "Structure-activity relationships of estradiol derivatives", CHEMICAL ABSTRACTS, (19791217), vol. 091, no. 25, Database accession no. 204845, page 97, column 2 [X] 1,3,4 * abstract * [Y] 1-4
    [ ] - YAO HSUEH HSUEH PAO, 1ST MED. COLL. SHANGHAI;DEP. PHARMACOL.; SHANGHAI; PEOP. R. CHINA, vol. 14, no. 6, pages 343 - 348
 [X]  - HOWARTH N M ET AL, "Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential", JOURNAL OF MEDICINAL CHEMISTRY, WASHINGTON US, (19940121), vol. 37, no. 2, pages 219 - 221 [X] 1,3,4 * page 219; examples 4-6 *
 [Y]  - J. KALVODA ET AL, "7-alpha-Methylöstrogene", HELVETICA CHIMICA ACTA, BASEL CH, vol. 50, no. 1, pages 281 - 288 [Y] 1-4 * page 282 - page 283; examples V,IX,XI,XV *
 [Y]  - N. UBEROI ET AL, "Structure Activity Reltionships of some Unique Estrogens Related to Estradiol Are Predicted by Fit into DNA", STEROIDS, SAN FRANCISCO US, vol. 45, no. 3-4, pages 325 - 340 [Y] 1-4 * page 325 - page 334 *
 [Y]  - R. PETERS ET AL, "17-Desoxy Estrogen Analogues", JOURNAL OF MEDICINAL CHEMISTRY, WASHINGTON US, vol. 32, no. 7, pages 1642 - 1652 [Y] 1-4 * page 1646; table II *
 [Y]  - B. BHAVNANI ET AL, "Interaction of Ring-B Unsaturated Estrogens with Estrogen Receptors of Human Endometrium and Rat Uterus", STEROIDS: STRUCTURE, FUNCTION, AND REGULATION, MA US, vol. 56, no. 4, pages 201 - 210 [Y] 1-4 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.